Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Sherief Abd-Elsalam

Status and phase: Unknown; Phase 3

Conditions: Portal Vein Thrombosis

Treatments: Drug: rivaroxaban

Study type: Interventional

Funder types: Other

Identifiers

NCT03193502

Amr Hanafy

Details and patient eligibility

About

-Rivaroxaban is factor Xa inhibitor

Full description

PVT is a common complication of liver cirrhosis

Enrollment: 40 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute PVT

Exclusion criteria

• Malignant PVT
• Bleeding disorders

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Portal Vein thrombosis

Experimental group

Description:

rivaroxaban

Treatment:

Drug: rivaroxaban